Aurora Signs Agreement with Alion Pharmaceuticals and Specs
Complete the form below to unlock access to ALL audio articles.
Aurora Biomed Inc. has announced that it has signed an agreement with Alion Pharmaceuticals and Specs to form a new Ion Channel Consortium that will provide a novel, comprehensive solution for ion channel drug discovery.
Together, the three companies will offer value added identification and validation of ion channel modulators.
The Ion Channel Consortium combines Alion’s proprietary method for short-listing drug candidates, Specs’ reliable sourcing and synthesis of compounds, and Aurora’s superior patch clamp services.
Researchers now have an option that enables time and cost savings while providing a unique method to identify new drug candidates for channelopathies.
